代表取締役社長
KAICO
KAICO utilizes a silkworm-baculovirus expression system to produce hard-expressing proteins for drug development, addressing the challenge of low protein yield in traditional expression systems. This technology enhances the efficiency and scalability of biopharmaceutical production, enabling faster and more cost-effective drug development.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$7.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional protein expression systems often struggle to produce sufficient yields of hard-to-express proteins, hindering drug development and biopharmaceutical research. Low protein yield can lead to increased costs, longer development timelines, and limitations in the types of proteins that can be effectively produced.
Solution
KAICO leverages a silkworm-baculovirus expression system to overcome the limitations of conventional protein production methods. This platform enables the efficient and scalable production of recombinant proteins, including those that are difficult to express using other systems. By utilizing silkworms as bioreactors, KAICO can achieve high-quality protein production, supporting the development of novel therapeutics, research reagents, supplements, and vaccines. The technology offers a cost-effective and reliable solution for producing complex proteins, accelerating biopharmaceutical innovation.
Target Audience
KAICO's primary customers include biopharmaceutical companies, research institutions, and vaccine developers seeking efficient and scalable protein production solutions.
Features
- Silkworm-baculovirus expression system for enhanced protein production
- Proprietary baculovirus genome and gene design expertise
- High-quality protein production, even for difficult-to-express proteins
- GMP facility for quality-controlled manufacturing
- Custom protein expression services for research and development
- Production of research reagents, supplements, and vaccines
- Veterinary and human vaccine development programs